Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/14/2899087/0/en/LIXTE-Biotechnology-Holdings-announces-collaboration-on-a-New-Colon-Cancer-Clinical-Trial.html
https://www.globenewswire.com/news-release/2024/06/06/2894649/0/en/Scientific-Journal-Reports-Findings-that-Show-LIXTE-s-Lead-Clinical-Compound-LB-100-Increases-Recognition-of-Colon-Cancer-Cells-by-the-Immune-System.html
https://www.globenewswire.com/news-release/2024/06/03/2892242/0/en/LIXTE-Biotechnology-Holdings-Names-Distinguished-Oncologist-Jan-Schellens-as-Chief-Medical-Officer.html
https://www.globenewswire.com/news-release/2024/05/20/2884852/0/en/LIXTE-Biotechnology-Holdings-Provides-Update-on-Recent-Activities.html
https://www.globenewswire.com/news-release/2024/05/08/2877913/0/en/LIXTE-Biotechnology-Co-Sponsoring-International-Scientific-Conference-on-Therapeutic-Over-Activation-in-Cancer.html
https://www.globenewswire.com/news-release/2024/03/27/2853169/0/en/NEW-SCIENTIFIC-PUBLICATION-SHOWS-LB-100-LIXTE-S-LEAD-CLINICAL-COMPOUND-CAN-FORCE-CANCER-CELLS-TO-GIVE-UP-THEIR-CANCER-CAUSING-PROPERTIES.html
https://www.globenewswire.com/news-release/2024/03/21/2850210/0/en/LIXTE-Provides-Update-on-Progress-with-LB-100-as-a-PP2A-Inhibitor-to-Enhance-Chemotherapy-and-Immunotherapy-Cancer-Treatments.html
https://www.globenewswire.com/news-release/2024/01/29/2818900/0/en/First-Patient-Dosed-with-LIXTE-s-LB-100-and-GSK-s-Immunotherapy-Dostarlimab-gxly-in-Ovarian-Clear-Cell-Carcinoma-Trial.html
https://www.globenewswire.com//news-release/2023/11/13/2779074/0/en/LIXTE-Biotechnology-Provides-Update-on-Clinical-Progress-and-Expanding-Collaborations.html
https://www.globenewswire.com//news-release/2023/10/16/2760671/0/en/LIXTE-Netherlands-Cancer-Institute-and-Oncode-Institute-to-Expand-Collaboration.html